Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data
Adamis shares slump as FDA declines to approve opioid overdose treatment
© Reuters. Adamis shares slump as FDA declines to approve opioid overdose treatment
By Shivani Singh
(Reuters) - Adamis Pharmaceuticals Corp (O:ADMP) said on Monday the U.S. Food and Drug Administration declined to approve its opioid overdose treatment, Zimhi, sending its shares plunging 56%.
In a so-called complete response letter (CRL), the FDA questioned the treatment's chemistry, manufacturing and controls process, but not its safety or effectiveness, the company said.
The drug is a naloxone pre-filled single dose syringe used for emergency treatment of known or suspected opioid overdose, and investors hoped the treatment would help the San Diego-based company reduce its reliance on its emergency allergy shot, Symjepi.
Adamis Pharmaceuticals had revenue of about $5.9 million in the third quarter, a 54% jump from a year earlier on Symjepi demand.
Maxim (NASDAQ:MXIM) Group analyst Jason McCarthy in a note, ahead of FDA's decision, estimated Zimhi to bring in peak sales of $70.8 mln in 2028.
"We believe the comments and recommendations stated in the CRL are manageable and plan to fully cooperate with the FDA," Adamis Chief Executive Dennis Carlo said in a statement.
The company said it will request a meeting with the FDA "as soon as reasonably possible" and plans to resubmit its application for approval.
Adamis is seeking to use Zimhi, which delivers high doses of naloxone, as part of the fight against the opioid crisis in the United States.
Opioids were involved in nearly 400,000 overdose deaths in the United States from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.
The U.S. Department of Health and Human Services last December had recommended prescribing or co-prescribing naloxone to high-risk patients for opioid overdose.
The company's shares were at 54 cents in morning trading. They had fallen 44% this year, through Friday's close.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.